ZYL 3177X

Drug Profile

ZYL 3177X

Alternative Names: ZYL3177X

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zylera Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 17 Nov 2017 Zylera Pharmaceuticals was acquired by Cerecor as result of the acquisition of TRx pharma
  • 28 Dec 2015 Phase-II clinical trials in Undefined indication in USA (unspecified route)
  • 26 Apr 2012 ZYL 3177X is available for licensing as of 26 Apr 2012. http://www.zylera.com/research-and-development/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top